U.S. Markets

Gilead (GILD) executive says Anito-Cel could address an up to USD 20bln multiple myeloma opportunity when considering use in first-line treatment, via TD Conference

1 stocks

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactions

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

See more